New York Stock Exchange Accepts InspireMD’s Plan to Regain Compliance

[junkie-button url=”http://infomeddnews.com/” style=”grey” size=”medium” type=”round” target=”_blank”] HOME [/junkie-button]

[junkie-alert style=”red”] InspireMD, Inc. (NYSE AMER: NSPR) (NYSE AMER: NSPR.WS) (“InspireMD” or the “Company”), embolic prevention systems, / thrombus management technologies and neurovascular devices, today announced that the New York Stock Exchange has accepted the Company’s plan to regain compliance with the NYSE American’s stockholder’s equity continued listing standard (Part 10, Section 1003(a)(iii)). As previously disclosed, the NYSE American notified the Company on August 17, 2017, that it had fallen below the NYSE’s continued listing standards. [/junkie-alert]

Based upon a review of the compliance plan and information submitted by the Company, the Exchange determined that the Company made a reasonable demonstration of its ability to make substantial progress toward regaining compliance with Section 1003(a)(iii) of the Company Guide by February 17, 2018.

The Company will be subject to periodic review by the exchange staff during the period covered by the plan. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the plan period could result in the Company’s shares being delisted from the Exchange.